Thu Nov 27 05:12:17 SGT 2014  
    Botox® jaw reduction, Singapore (SG)

Botox® jaw reduction, Singapore (SG)


Botox® jaw reduction, Singapore (SG) @singaporebotox_com: Botox® Cosmetic, Dysport®, BTX-A, botulinum toxin type A injection, wrinkle removal treatment clinic, Singapore. Cost/price for treating glabella frown lines, crow's feet, and horizontal forehead lines. Definitions, references, and latest news.


Jaw slimming / face slimming / Botox® jaw reduction / Botox® jaw slimming / Botox® face slimming price.

AreaIU/spotSpotsTotal IUPrice @ SG$15/IU
Jaw reduction8 to 12656SG$840

Botox® price. Average Botox® cost.

AreaIU/spotSpotsTotal IUPrice @ SG$15/IU
Horizontal forehead lines2816SG$240
Glabellar frown lines4520SG$300
Crow's feet4624SG$360

Botox® is one of the trade names for botulinum toxin, which is a protein produced by the bacterium clostridium botulinum.

Botox® treatment is with the original Allergan Botox® Cosmetic

  • The units differ for different brands.
  • Price quoted is for average ladies face, with average musculature.
  • Muscular men might require up to twice as much.
  • Minimum charge is for 10 units.

Aesthetic services available:

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Botox® jaw reduction, Singapore (SG)
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.


Latest News

Botulinum Toxin Type B: pH Change Reduces Injection Pain, Retains Efficacy
Tue, 25 Nov 2014 22:56:20 +0100 | Dermatologic Surgery
CONCLUSION: Botulinum toxin Type A resistance is documented to 3 BTX-A brands in 2 patients. They had received low doses of Type A toxin, they responded to Type B toxin. Injection pain of the acidic solution of BTX-B neurotoxin was reduced and efficacy not compromised by changing pH of BTX-B solution to pH 7.5. This method improved patient tolerance to BTX-B injections. (Source: Dermatologic Surgery)

Danielle Sheehan's life transformed after Botox eradicates her eczema
Tue, 25 Nov 2014 18:11:56 +0100 | the Mail online | Health
EXCLUSIVE: Danielle Sheehan, 24, from Lowestoft in Suffolk, had Botox for the first time 18 months ago. Five days later she noticed her eczema had suddenly cleared for the first time in years. (Source: the Mail online | Health)

Botulinum toxin in neurogenic detrusor overactivity.
Tue, 25 Nov 2014 02:40:03 +0100 | International Neurourology Journal
CONCLUSIONS: A botulinum toxin type A showed a significantly improved response in urodynamics parameters and specific and general quality of life.

Actavis Wins Bid To Buy Allergan
Fri, 21 Nov 2014 03:36:46 +0100 | Chemical and Engineering News
Pharmaceuticals: Botox maker avoids takeover by Valeant, sealing deal to preserve more of its R&D (Source: Chemical and Engineering News)

The Inhibitory Effect of Platelet-Rich Plasma on Botulinum Toxin Type-A: An Experimental Study in Rabbits
Fri, 21 Nov 2014 00:00:00 +0100 | Aesthetic Plastic Surgery

Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia
Wed, 19 Nov 2014 00:00:00 +0100 | Parkinsonism and Related Disorders
The development of secondary non-response (SNR) to botulinum neurotoxin type-A (BoNT-A) is considered a key issue in the management of cervical dystonia (CD). This case-controlled study was performed to systematically identify factors influencing SNR during BoNT-A therapy. (Source: Parkinsonism and Related Disorders)

The cost‐effectiveness of sacral nerve stimulation for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK
Wed, 19 Nov 2014 00:00:00 +0100 | BJU International
ConclusionIn the management of patients with idiopathic OAB wet, the results of this cost‐utility analysis favors SNS (PNE or TLE) over PTNS or OMT, and the most efficient treatment strategy is SNS PNE over BoNT‐A over a 10 year period. (Source: BJU International)

Understanding and treating vaginismus: a multimodal approach
Tue, 18 Nov 2014 13:13:21 +0100 | International Urogynecology Journal

Snapshot: Botox maker’s $66B deal + Ford debuts 500-horsepower Mustang
Tue, 18 Nov 2014 13:12:00 +0100 | Health Care:Pharmaceuticals headlines

Actavis to Buy Allergan for $66 Billion
Tue, 18 Nov 2014 02:18:49 +0100 | Health
Actavis agreed to pay $66 billion in cash and stock for Allergan in a deal that appears to have thwarted a hostile takeover of the Botox maker by Valeant and Bill Ackman. (Source: Health)